CNBC's "Fast Money" Eli Lilly’s Sales Slash… And How To Position Ahead Of Bank Results 1/14/25
10 snips
Jan 14, 2025 Eli Lilly’s stock faces challenges after cutting its sales outlook, sparking debates on investment opportunities. Insights from JP Morgan’s Health Care Conference reveal market reactions and competitor dynamics. Economic indicators like PPI are examined alongside the Federal Reserve’s cautious strategies amid inflation. Boeing's delivery troubles add contrast, while quantum stocks show promising rebounds. The banking sector’s yield curve dynamics are explored, particularly around profitability, as discussions shift to crucial earnings season analysis.
AI Snips
Chapters
Transcript
Episode notes
Eli Lilly Stock Drop
- Eli Lilly's stock dropped significantly after a disappointing Q4 revenue outlook.
- Sales of its blockbuster drugs, Mounjaro and Trulicity, are growing slower than anticipated.
Buying Opportunity?
- Mizuho Healthcare Strategist Jared Holz sees Eli Lilly's stock weakness as a buying opportunity.
- He believes the market is still in early stages for these drugs, despite current valuation concerns.
Gains Gone
- Eli Lilly's stock price has retraced all gains made since before Mounjaro and Trulicity were approved.
- The situation is compared to the hype cycle seen with AI stocks.